Wang, D., Liu, H., Chen, L., He, M., Zhao, W., Xiang, Y., Wang, G., Zhang, G. (2025). A phase II study of anlotinib plus penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Results from ALTER-GO-020 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.5527